Anti-obesity drugs 'fail to reduce weight'

Anti-obesity drugs are unlikely to permanently reduce patients’ weight, Canadian research findings suggests.

A meta-analysis showed little evidence that orlistat, sibutramine or rimonabant reduced patients’ weight loss by 5 per cent.

Such ‘modest’ weight loss could mean many patients will remain significantly overweight or obese despite drug treatment, say the researchers.

The study focused on 30 randomised placebo-controlled studies into anti-obesity drugs, involving almost 20,000 patients treated for at least one year.

Analysis showed that compared with placebo, orlistat reduced weight by an average of 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. As the average starting weight of participants was 100kg, the drugs often failed to reduce body weight by 5 per cent.

Of note, 30-40 per cent of participants dropped out of the trials, potentially affecting perceived effectiveness of the drug.

Last December, NICE published public health guidance on obesity. Use of orlistat and sibutramine were recommended if patients with a BMI of 30 or more fail to respond to lifestyle interventions.

However, treatment should only be continued beyond six months if the patient manages to lose 5 per cent body weight in that time, according to NICE.

NICE is also carrying out a technology appraisal into rimonabant, which was licensed by the EMEA last June.

rachel.liddle@haymarket.com

Visit the BMJ website

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GMC to restart fitness to practise cases and PLAB tests within weeks

GMC to restart fitness to practise cases and PLAB tests within weeks

Fitness to practise cases paused during the coronavirus pandemic will restart this...

NHS England confirms plan to add practice managers to £20,000 golden hello scheme

NHS England confirms plan to add practice managers to £20,000 golden hello scheme

NHS England hopes to extend the £20,000 golden hello scheme for first-time partners...

COVID-19 risk assessments could devastate fragile GP workforce in parts of England

COVID-19 risk assessments could devastate fragile GP workforce in parts of England

COVID-19 risk assessments could devastate the threadbare primary care workforce in...

GP trainees still paying thousands for NHS levy Boris Johnson promised to scrap

GP trainees still paying thousands for NHS levy Boris Johnson promised to scrap

GP trainees are among overseas NHS staff continuing to face demands for thousands...

GP fear surge of avoidable illness as patients skip routine vaccinations in pandemic

GP fear surge of avoidable illness as patients skip routine vaccinations in pandemic

Patients have been urged not to skip routine vaccination amid concerns the COVID-19...

GPs plan drive-through flu clinics amid COVID-19 safety fears

GPs plan drive-through flu clinics amid COVID-19 safety fears

GP practices are planning drive-through flu clinics to maximise uptake of jabs during...